These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
76 related articles for article (PubMed ID: 20728785)
21. Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Juhász M; Herszényi L; Tulassay Z Digestion; 2010; 81(1):10-5. PubMed ID: 20029203 [TBL] [Abstract][Full Text] [Related]
22. Proton pump inhibitor and clopidogrel interaction: the case for watchful waiting. Tan VP; Yan BP; Hunt RH; Wong BC J Gastroenterol Hepatol; 2010 Aug; 25(8):1342-7. PubMed ID: 20659222 [TBL] [Abstract][Full Text] [Related]
23. Severe intoxication with methotrexate possibly associated with concomitant use of proton pump inhibitors. Santucci R; Levêque D; Kemmel V; Lutz P; Gérout AC; N'guyen A; Lescoute A; Schneider F; Bergerat JP; Herbrecht R Anticancer Res; 2010 Mar; 30(3):963-5. PubMed ID: 20393020 [TBL] [Abstract][Full Text] [Related]
24. Management of patients with high gastrointestinal risk on antiplatelet therapy. Cryer B Gastroenterol Clin North Am; 2009 Jun; 38(2):289-303. PubMed ID: 19446259 [TBL] [Abstract][Full Text] [Related]
25. Potential Interaction between clopidogrel and proton pump inhibitors. Howard PA; Vacek JL Am J Cardiovasc Drugs; 2009; 9(6):353-9. PubMed ID: 19929033 [TBL] [Abstract][Full Text] [Related]
27. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia. Kostapanos MS; Milionis HJ; Elisaf MS Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931 [TBL] [Abstract][Full Text] [Related]
28. Risk of adverse outcomes in Taiwan associated with concomitant use of clopidogrel and proton pump inhibitors in patients who received percutaneous coronary intervention. Huang CC; Chen YC; Leu HB; Chen TJ; Lin SJ; Chan WL; Chen JW Am J Cardiol; 2010 Jun; 105(12):1705-9. PubMed ID: 20538118 [TBL] [Abstract][Full Text] [Related]
29. Adverse drug reactions due to drug-drug interactions with proton pump inhibitors: assessment of systematic reviews with AMSTAR method. Yucel E; Sancar M; Yucel A; Okuyan B Expert Opin Drug Saf; 2016; 15(2):223-36. PubMed ID: 26635063 [TBL] [Abstract][Full Text] [Related]
31. Long-term acid control and proton pump inhibitors: interactions and safety issues in perspective. Freston JW Am J Gastroenterol; 1997 Apr; 92(4 Suppl):51S-55S; discussion 55S-57S. PubMed ID: 9127627 [TBL] [Abstract][Full Text] [Related]
32. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Smelick GS; Heffron TP; Chu L; Dean B; West DA; Duvall SL; Lum BL; Budha N; Holden SN; Benet LZ; Frymoyer A; Dresser MJ; Ware JA Mol Pharm; 2013 Nov; 10(11):4055-62. PubMed ID: 24044612 [TBL] [Abstract][Full Text] [Related]
34. In silico design of novel proton-pump inhibitors with reduced adverse effects. Li X; Kang H; Liu W; Singhal S; Jiao N; Wang Y; Zhu L; Zhu R Front Med; 2019 Apr; 13(2):277-284. PubMed ID: 29845582 [TBL] [Abstract][Full Text] [Related]
35. Pharmacogenetics of PPIs: Lessons Learned. Xie C; Wilke WA S D Med; 2017 Aug; 70(8):342-344. PubMed ID: 28813739 [No Abstract] [Full Text] [Related]